Heidelberg University Hospital / NCT / DKFZ
Heidelberg is Germany's cancer research capital, home to the DKFZ (largest cancer research institute in Germany) and the NCT, and the birthplace of FAPI PET and the brain tumour methylation classifier.
FAPI tracers (Haberkorn, Giesel, Kratochwil), 225Ac-PSMA first-in-human, Heidelberg Ion-Beam Therapy Center (carbon ions), DKFZ methylation classifier (Pfister, von Deimling), MASTER precision oncology programme.
- FAPI PET
- Alpha PSMA therapy
- Carbon-ion therapy
- CNS methylation classifier
- DKFZ basic research
Co-created the DNA methylation classifier that changed how brain tumours are diagnosed worldwide.
Clemens Kratochwil reported the first patients treated with actinium-225 PSMA therapy.
Frederik Giesel co-developed FAPI PET imaging and now leads nuclear medicine in Düsseldorf.
Jürgen Debus leads Europe's pioneering heavy-ion therapy centre.
Runs the NCT/DKTK MASTER programme that sequences whole genomes of rare and young-adult cancers to guide therapy.
Paediatric oncologist whose genomic work redefined childhood brain tumours into molecular subgroups.
Nuclear medicine physician whose group invented FAPI PET tracers and pioneered PSMA and FAP radioligand therapy.